Compound
← Compound
Official website →
SNYSanofi
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- SNY
- Moeda das demonstrações
- EUR
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions:…
IndustryDrug Manufacturers - General
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
22.65×
P/B
Price divided by book value
1.28×
EV/EBITDA
Enterprise value divided by operating cash generation
12.87×
EV/Revenue
Enterprise value divided by revenue
2.17×
What the company earns
ROE
Return on shareholders’ equity
5.5%
ROA
Return on all assets
3.1%
Gross margin
What remains after product costs
72.8%
Operating margin
What remains after operating the business
20.6%
Net margin
How much of each revenue unit becomes profit
8.1%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
0.34
Total debt
Sum of borrowings
€23.58B
Cash
Cash available to cover it
€6.35B
Current ratio
Short-term assets divided by short-term liabilities
0.99
Free cash flow
Cash left after investing
€3.9B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.28
Revenue growth
Compared with the same period a year earlier
14.6%
Earnings growth
Compared with the same period a year earlier
-91.3%
Dividend yield
Trailing 12-month distributions divided by price
11.3%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(EUR)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Custo dos produtos | -11.88B | -12.63B | -13.21B | -13.05B |
| Lucro bruto | 28.68B | 28.99B | 31.08B | 33.67B |
| Pesquisa e desenvolvimento | -6.5B | -6.51B | -7.39B | -7.84B |
| Resultado operacional | 10.16B |
News about SNY
Yahoo Finance · 7 days ago
Cheplapharm to take over 20 medicines and three sites from Sanofi
Follow SNY and get agent analysis of what is moving the stock.
Open Compound